Dermoscopic Evaluation of Amelanotic and Hypomelanotic Melanoma
Scott W. Menzies(Royal Prince Alfred Hospital), Robert H. Johr, David Langford, G. Ghigliotti(Alleanza Contro il Cancro), Harold Rabinovitz(Pontificia Universidad Católica de Chile), Karin Terstappen, H. Peter Soyer(The University of Queensland), Ralph P. Braun, R. Bono(Istituto Dermopatico dell'Immacolata), Domenico Piccolo(Azienda USL di Pescara), Josep Malvehy(Universitat de Barcelona), Karen Byth(Westmead Hospital), Masaru Tanaka, Pascale Guitera(The University of Sydney), Ignazio Stanganelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Álex Llambrich, Giuseppe Argenziano(Regione Campania), Michelle Avramidis(The University of Sydney), Susana Puig(Instituto de Salud Carlos III), Maria Antonietta Pizzichetta(University of Trieste), L. Thomas(University of Liverpool), Verena Ahlgrimm‐Siess, Gianluca Pagnanelli, Iris Zalaudek(Azienda Sanitaria Universitaria Integrata di Trieste), Margaret Oliviero, Ashfaq A. Marghoob(Memorial Sloan Kettering Cancer Center), Horacio Cabo, Giovanni Pellacani(Sapienza University of Rome), Juergen Kreusch, Ana M. Perusquia
Cited by 304
Related Papers
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2016|1k
Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines
|European Journal of Cancer|2019|589
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2017|491
Epidemiology and Host- and Variety-Dependent Characteristics of Infection Due to Cryptococcus neoformans in Australia and New Zealand
|Clinical Infectious Diseases|2000|464